Estradiol derivative and estratopone containing sustained release intraocular implants and related methods

• US 20050244471A1
• Filed: 04/30/2004
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Dickinson, Paul W., Shiah, Jane Guo
• Application Number:
  US10/837,379
• Publication Number:
  US 20050244471A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Biocompatible intraocular implants include an anti-angiogenic agent, such as estradiol derivative or an estratopone and a biodegradable polymer that is effective to facilitate release of the anti-angiogenic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as angiogenisis, ocular tumors, and the like.

Claims

1. A biodegradable intraocular implant comprising:

an estradiol derivative and a biodegradable polymer matrix that is substantially free of a polyvinyl alcohol and that releases drug at a rate effective to sustain release of an amount of the estradiol derivative from the implant for at least about one week after the implant is placed in an eye.

2. The implant of claim 1, wherein the estradiol derivative is a compound having the following formula:

wherein;

I. R_a-R_o are defined as follows;

A) each R_a, R_b, R_c, R_d, R_e, R_f, R_i, R_j, R_k, R_L, R_m, R_o, independently is —

R₁, —

OR₁, —

OCOR₁, —

SR₁, —

F, —

NHR₂, —

Br, —

I; and

R_g is —

R, —

OR₁, —

OCOR₁, —

SR1, —

F, —

NHR₂, —

Br, —

I, or —

C≡

CH;

or

B) each R_a, R_b, R_c, R_f, R_k, R_L, R_o, independently is —

R₁, —

OR₁, —

OCOR₁, —

SR₁, —

F, —

NHR₂, —

Br, or —

I; and

each R_d, R_e, R₁, R_m, independently is ═

O, —

R₁, —

OR₁, —

OCOR₁, —

SR₁, —

F, —

NHR₂, —

Br or —

I; and

R_g is ═

O, —

R₁, —

OR₁, —

OCOR₁, —

SR₁, —

F, —

NHR₂, —

BR, —

I, or —

C≡

CH

II. Z′

is defined as follows;

where R_n is —

R₁, —

OR₁, —

SR₁, —

F, —

NHR₂, —

BR or —

I; and

X′

is X, as defined above;

or X′

is >

C═

O; and

III. Z″

is defined as follows;

A) Z″

is Y, where Y is

where n is 0-6;

or

B) Z″

is

where R_p is —

R₁, OR₁, —

SR₁, —

F, —

NHR₂, —

Br or —

I and Y is defined as in III (A); and

IV. provided that when each Rb, Rc, Rd, Rc, Ri, Rj, Rk, RL, Rm, and Ro is H;

R_f is —

CH₃;

R_g is —

OH;

Z′

is >

COH; and

Z″

is >

CH2;

then R_a is not —

H;

where, in each formula set forth above, each R₁ and R₂ independently is —

H, or a substituted or unsubstituted alkyl, alkenyl or alkynl group of up to 6 carbons.

3. The implant of claim 1, wherein the estradiol derivative is 2-methoxyestradiol, salts thereof, and mixtures thereof.

4. The implant of claim 1, further comprising an additional ophthalmically acceptable therapeutic agent.

5. The implant of claim 1, wherein the estradiol derivative is dispersed within the biodegradable polymer matrix.

6. The implant of claim 1, further comprising a solubility enhancing component provided in an amount effective to enhance the solubility of the estradiol derivative relative to an substantially identical implant without the solubility enhancing component.

7. The implant of claim 6, wherein the solubility enhancing component comprises β

-cyclodextrin.

8. The implant of claim 7, wherein the β

-cyclodextrin is provided in an amount from about 0.5% (w/w) to about 25% (w/w) of the implant.

9. The implant of claim 8, wherein the p-cyclodextrin is provided in an amount from about 0.5% (w/w) to about 15% (w/w) of the implant.

10. The implant of claim 1, wherein the matrix comprises at least one polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), derivatives thereof, and mixtures thereof.

11. The implant of claim 1, wherein the matrix comprises a poly (lactide-co-glycolide).

12. The implant of claim 1, wherein the matrix comprises a poly(D,L-lactide-co-glycolide).

13. The implant of claim 1, wherein the matrix releases drug at a rate effective to sustain release of an amount of the estradiol derivative from the implant for more than one month from the time the implant is placed in the vitreous of the eye.

14. The implant of claim 1, wherein the estradiol derivative is 2-methoxyestradiol, and the matrix releases drug at a rate effective to sustain release of a therapeutically effective amount of the 2-methoxyestradiol for a time from about two months to about six months.

15. The implant of claim 1, wherein the implant is structured to be placed in the vitreous of the eye.

16. The implant of claim 1, wherein the estradiol derivative is a 2-methoxyestradiol provided in an amount from about 40% by weight to about 70% by weight of the implant, and the biodegradable polymer matrix comprises a poly (lactide-co-glycolide) in an amount from about 30% by weight to about 60% by weight of the implant.

17. The implant of claim 1 formed as a rod, a wafer, or a particle.

18. The implant of claim 1 which is formed by an extrusion process.

19. A biodegradable intraocular implant comprising:

an estratopone and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the estratopone from the implant for at least about one week after the implant is placed in an eye.

20. The implant of claim 19, wherein the estratopone is a compound having the following formula

wherein A is a fused tropone having a general formula:

wherein X is selected from the group consisting of H, Cl, Br, methoxy and ethoxy.

21. The implant of claim 19, wherein the estratopone is a compound having the following formula

wherein A is

wherein X is selected from the group consisting of chloro and bromo.

22. The implant of claim 19, wherein the estratopone is a compound having the following formula

wherein A is

and X is methoxy.

23. The implant of claim 19, further comprising an additional ophthalmically acceptable therapeutic agent.

24. The implant of claim 19, wherein the estratopone is dispersed within the biodegradable polymer matrix.

25. The implant of claim 20, further comprising a solubility enhancing component provided in an amount effective to enhance the solubility of the estradiol derivative relative to an substantially identical implant without the solubility enhancing component.

26. The implant of claim 25, wherein the solubility enhancing component comprises β

-cyclodextrin.

27. The implant of claim 26, wherein the β

-cyclodextrin is provided in an amount from about 0.5% (w/w) to about 25% (w/w) of the implant.

28. The implant of claim 19, wherein the matrix comprises at least one polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), derivatives thereof, and mixtures thereof.

29. The implant of claim 19, wherein the matrix is substantially free of a polyvinyl alcohol.

30. The implant of claim 19, wherein the matrix releases drug at a rate effective to sustain release of an amount of the estratopone from the implant for more than one month from the time the implant is placed in the vitreous of the eye.

31. The implant of claim 19, wherein the implant is structured to be placed in the vitreous of the eye.

32. The implant of claim 19, wherein the estratopone is provided in an amount from about 20% by weight to about 80% by weight of the implant, and the biodegradable polymer matrix comprises a poly (lactide-co-glycolide) in an amount from about 20% by weight to about 80% by weight of the implant.

33. The implant of claim 19 formed as a rod, a wafer, or a particle.

34. The implant of claim 19 which is formed by an extrusion process.

35. A method of making a biodegradable intraocular implant, comprising the step of:

extruding a mixture of an estradiol derivative or an estratopone and a biodegradable polymer component to form a biodegradable material that degrades at a rate effective to sustain release of an amount of the estradiol derivative or an estratopone from the implant for at least about one week after the implant is placed in an eye.

36. The method of claim 35, wherein mixture consists essentially of 2-methoxyestradiol and a biodegradable polymer.

37. The method of claim 35, further comprising a step of mixing the estradiol derivative or estratopone with the polymer component before the extrusion step.

38. The method of claim 35, wherein the estradiol derivative or estratopone and the polymer component are in a powder form.

39. The method of claim 35, wherein the polymer component comprises a polymer selected from the group consisting of polylactides, poly (lactide-co-glycolides), and combinations thereof.

40. The method of claim 35, wherein the polymer component is substantially free of polyvinyl alcohol.

41. A method of treating an ocular condition characterized by undesirable angiogenisis in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising (i) an estradiol derivative and a biodegradable polymer matrix substantially free of polyvinyl alcohol, or (ii) an estratopone and a biodegradable polymer matrix, wherein the implant degrades at a rate effective to sustain release of an amount of the estradiol derivative or estratopone from the implant effective to reduce angiogenisis in the eye of the patient.

42. The method of claim 41, wherein the method is effective to treat a retinal ocular condition.

43. The method of claim 41, wherein the ocular condition is a condition selected from the group consisting of ocular tumors, vascular malfunctions, Bechet'"'"'s disease, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma and Osler Weber syndrome.

44. The method of claim 41, wherein the implant is placed in the posterior of the eye.

45. The method of claim 41, wherein the implant is placed in the eye with a trocar.

46. The method of claim 41, wherein the implant is placed in the eye with a syringe.

47. The method of claim 41, further comprising a step of administering a therapeutic agent in addition to the estradiol derivative or estratopone to the patient.

48. The method of claim 41, wherein the estradiol derivative is 2-methoxyestradiol, salts thereof, and mixtures thereof.

49. A biodegradable intraocular implant comprising:

an anti-angiogenic agent and a biodegradable polymer matrix that is substantially free of a polyvinyl alcohol and that releases drug at a rate effective to sustain release of an amount of the anti-angiogenic agent from the implant for at least about one week after the implant is placed in an eye.

50. A biodegradable intraocular implant comprising:

anacortate and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the anacortate from the implant for at least about one week after the implant is placed in an eye.